[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638288":3},{"organization":4,"armGroups":7,"interventions":43,"overallOfficials":48,"centralContacts":77,"locations":48,"responsibleParty":83,"collaborators":48,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":48,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":48,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":48,"overallStatus":104,"whyStopped":48,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,16,22,28,33,38],{"label":9,"type":10,"description":11,"interventionNames":12},"Laroprovstat","ACTIVE_COMPARATOR","The patient will receive a daily dose of Laroprovstat",[13,14,15],"Drug: Laroprovstat","Drug: Placebo to match rosuvastatin","Drug: Placebo to match Laroprovstat\u002FRosuvastatin 2",{"label":17,"type":18,"description":19,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR","The patient will receive a daily dose of Placebo",[14,21,15],"Drug: Placebo to match Laroprovstat and Laroprovstat\u002FRosuvastatin 1",{"label":23,"type":24,"description":25,"interventionNames":26},"Laroprovstat\u002FRosuvastatin dose combination 1","EXPERIMENTAL","The patient will receive a daily dose of Laroprovstat\u002FRosuvastatin 1",[27,14,15],"Drug: Laroprovstat\u002FRosuvastatin 1",{"label":29,"type":24,"description":30,"interventionNames":31},"Laroprovstat\u002FRosuvastatin dose combination 2","The patient will receive a daily dose of Laroprovstat\u002FRosuvastatin 2",[14,21,32],"Drug: Laroprovstat\u002FRosuvastatin 2",{"label":34,"type":10,"description":35,"interventionNames":36},"Rosuvastatin dose 1","The patient will receive a daily dose of Rosuvastatin 1",[37,21,15],"Drug: Rosuvastatin 1",{"label":39,"type":10,"description":40,"interventionNames":41},"Rosuvastatin dose 2","The patient will receive a daily dose of Rosuvastatin 2",[42,21,15],"Drug: Rosuvastatin 2",[44,49,53,57,61,65,69,73],{"type":45,"name":9,"description":46,"armGroupLabels":47,"otherNames":48},"DRUG","daily oral dose of the Laroprovstat",[9],null,{"type":45,"name":50,"description":51,"armGroupLabels":52,"otherNames":48},"Rosuvastatin 1","daily oral dose of the Rosuvastatin 1",[34],{"type":45,"name":54,"description":55,"armGroupLabels":56,"otherNames":48},"Rosuvastatin 2","daily oral dose of the Rosuvastatin 2",[39],{"type":45,"name":58,"description":59,"armGroupLabels":60,"otherNames":48},"Laroprovstat\u002FRosuvastatin 1","daily oral dose of the Laroprovstat\u002FRosuvastatin 1",[23],{"type":45,"name":62,"description":63,"armGroupLabels":64,"otherNames":48},"Placebo to match rosuvastatin","daily oral dose of the Placebo to match Rosuvastatin",[9,23,29,17],{"type":45,"name":66,"description":67,"armGroupLabels":68,"otherNames":48},"Placebo to match Laroprovstat and Laroprovstat\u002FRosuvastatin 1","daily oral dose of the Placebo to match Laroprovstat and Laroprovstat\u002FRosuvastatin 1",[29,17,34,39],{"type":45,"name":70,"description":71,"armGroupLabels":72,"otherNames":48},"Laroprovstat\u002FRosuvastatin 2","daily oral dose of the Laroprovstat\u002FRosuvastatin 2",[29],{"type":45,"name":74,"description":75,"armGroupLabels":76,"otherNames":48},"Placebo to match Laroprovstat\u002FRosuvastatin 2","daily oral dose of the Placebo to match Laroprovstat\u002FRosuvastatin 2",[9,23,17,34,39],[78],{"name":79,"role":80,"phone":81,"phoneExt":48,"email":82},"AstraZeneca Clinical Study Information Center","CONTACT","+18772409479","information.center@astrazeneca.com",{"type":84,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR","100638288","phase-3-a-phase-iii-study-to-assess-the-effect-of-fdc-laroprovstatrosuvastatin-compared-with-laroprovstat-rosuvastatin-and-placebo-on-ldl-c-in-llt-nave-patients-100638288",false,"NCT07619131","A Phase III Study to Assess the Effect of FDC Laroprovstat\u002FRosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.","A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat\u002FRosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age\n* Participants with no clinical history of atherosclerotic cardiovascular disease (ASCVD) and a 10-year ASCVD risk estimated as low\n* Participants who have not received any LLT in the 3 months prior to screening\n\nExclusion Criteria:\n\n* Asian origin.\n* Statin intolerance\n* Uncontrolled severe hypertension\n* Uncontrolled type 2 diabetes mellitus\n* Inadequately treated hypothyroidism","ALL","18 Years","130 Years",{"count":96,"type":97},600,"ESTIMATED","INTERVENTIONAL",[100],"PHASE3","This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat\u002Frosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat\u002Frosuvastatin are being developed for the treatment of hypercholesterolaemia.",[103],"Hypercholesterolaemia","NOT_YET_RECRUITING","2026-05-26",{"date":107,"type":108},"2026-06-01","ACTUAL",{"date":110,"type":97},"2026-08-17",{"date":112,"type":97},"2027-07-30",{"name":5,"class":6}]